Coronary Artery Disease
Coronary Artery Disease (CAD), also known as coronary heart disease (CHD) or ischemic heart disease (IHD), is a common cardiovascular condition caused by atherosclerosis, which leads to reduced blood flow to the heart muscle. Major risk factors include smoking, family history, high blood pressure, and high cholesterol, and it can manifest as stable angina, unstable angina, or myocardial infarction.
Health Outcomes
- Attenuated Blood Pressure (Inactivated Cells Only)
- Change in Waist-to-Hip Ratio
- Changed Leukocyte Telomere Length
- Controlled Serum Cholesterol Levels
- Decreased HDL Cholesterol Level
- Elevated Serum Lipoprotein Lipase Levels in Gilts
- Elevated Triglyceride Levels
- Endothelial Cell Damage
- Enhanced Aggregation Abilities
- Enhanced Antioxidant Levels
- Enhanced Cell Adherence
- Enhanced Co-aggregation Ability
- Enhanced Reverse Cholesterol Transport
- Extended Lifespan
- Identified ACE-Inhibitory Peptides
- Improved Aerobic Capacity
- Improved Aerobic Endurance Performance
- Improved Aerobic Power
- Improved Aerobic Stability
- Improved Angina Symptom
- Improved Antithrombotic Prevention
- Improved ApoB-100/ApoA-1 Ratio
- Improved Arginine Metabolism
- Improved Atherosclerosis-Related Cardiovascular Risk Markers
- Improved Blood Lipid Profile
- Improved Canadian Cardiovascular Society Angina Grade
- Improved Cardiac Baroreflex Sensitivity
- Improved Cardiac Muscle Contractile Performance
- Improved Cardiometabolic Health
- Improved Cardioprotective Activity
- Improved Cardiovascular Disease Marker
- Improved Cardiovascular Disease Outcomes
- Improved Cardiovascular Function
- Improved Cardiovascular Health
- Improved Cholesterol Levels
- Improved Cholesterol Metabolism
- Improved Cholesterol Profile
- Improved Cholesterol Regulation
- Improved Clinical Success
- Improved Disease Management
- Improved Endothelial Reactivity
- Improved Endothelium-Dependent Vasodilation
- Improved Endothelium-Dependent Vasodilation in Resistance Arteries
- Improved Endothelium-Independent Microvascular Vasodilation
- Improved Estimated VO2max
- Improved Event-Free Survival
- Improved Exercise Function
- Improved Exercise Stress Test Grade
- Improved Fibrinolytic Activity
- Improved Flow-Mediated Dilation
- Improved Flow-Mediated Vasodilation
- Improved Health Outcomes
- Improved Heart Rate Recovery
- Improved Imaging Findings
- Improved LDL Cholesterol
- Improved LDL-C to HDL-C Ratio
- Improved Left Ventricular Ejection Fraction
- Improved Left Ventricular Global Longitudinal Strain
- Improved Lipid Levels
- Improved Lipid Metabolism
- Improved Lipid Profile
- Improved Longevity
- Improved Low-Density Lipoprotein Composition
- Improved Maximal Exercise Capacity
- Improved Maximal Oxygen Uptake
- Improved Mean Arterial Pressure
- Improved Medication Adherence
- Improved Monocyte Activation
- Improved Myocardial Strain Rate
- Improved Physical Role Limitation
- Improved Plasma Cholesterol Clearance
- Improved Plasma Lipid Levels
- Improved Post-Myocardial Infarction Outcome
- Improved Prognosis of Type 2 Diabetes Mellitus
- Improved Reactive Hyperemia Index
- Improved Serum Lipids
- Improved Stress-Strain Index
- Improved Survival at 24 Months
- Improved Total Cholesterol Levels
- Improved VO2max
- Improved Vascular Endothelial Function
- Improved Vascular Function
- Improved Vascular Function in Offspring
- Improved Vasodilation
- Increased Apolipoprotein E Levels
- Increased Bioactivity
- Increased Body Mass Index
- Increased Bone Marrow Myelopoiesis
- Increased C-Reactive Protein Level
- Increased CD163+ Macrophage Density
- Increased CD68 to CD163 Ratio
- Increased CD68+ Macrophage Density
- Increased Circulating Vitamin K2 Levels
- Increased Endothelial Nitric Oxide Synthase Activity
- Increased Exercise Capacity
- Increased High-Density Lipoprotein Cholesterol
- Increased Homocysteine Level
- Increased Hospital Admissions
- Increased Inhibition of Lipid Oxidation
- Increased Invasive Interventions Requirement
- Increased LDL Cholesterol Level
- Increased Leptin Level
- Increased Lipid Oxidation
- Increased Myeloperoxidase Activity
- Increased Nattokinase Activity
- Increased Nitric Oxide Bioavailability
- Increased Nitric Oxide Metabolite Levels in Metabolic Syndrome Patients
- Increased Nitric Oxide Synthase Activity
- Increased Paraoxonase 1 Enzyme Activity
- Increased Physical Activity
- Increased Plasma Omega-3 Fatty Acids
- Increased SalA-like Inhibitory Activity
- Increased Serum High-Molecular Weight Adiponectin
- Increased Shear Force
- Increased Soluble Receptor of Advanced Glycation End Products
- Increased Triglyceride Level
- Increased n-3 Polyunsaturated Fatty Acid Levels
- Induced Health-Related Benefits
- Inhibited Lipid Oxidation
- Maintained High-Density Lipoprotein Levels
- Mitigated Cardiac Injury from Myocardial Infarction
- Multiple Health-Promoting Effects
- No Change in Major Cardiovascular Event
- No Improvement in Total Cholesterol
- No Reduction in Meat Cholesterol Levels
- No Significant Effect on Anxiety Levels
- Normalized Lipid Metabolism
- Normalized Serum Lipid Levels
- Prevention of Hypercholesterolemia
- Reduced Adverse Physiometabolic Effects
- Reduced Anger and Hostility
- Reduced Aortic Superoxide Levels
- Reduced Aortic Thickness
- Reduced Apelin Gene Expression
- Reduced Apolipoprotein B Levels
- Reduced Apolipoprotein B to A-1 Ratio
- Reduced Apolipoprotein B-100
- Reduced Apolipoprotein B-100 to Apolipoprotein A-1 Ratio
- Reduced Arterial Calcifying Lesion Development
- Reduced Arterial Stiffness
- Reduced Atherogenic Index
- Reduced Atherosclerosis Risk Factors
- Reduced Atherosclerotic Cardiovascular Disease Event
- Reduced Atherosclerotic Plaque Formation
- Reduced Blood Cholesterol
- Reduced Blood Lipid Levels
- Reduced Blood Serum Cholesterol
- Reduced Blood Stream Cholesterol
- Reduced C-Reactive Protein Level
- Reduced Cardiac Arrest Risk
- Reduced Cardiac Function
- Reduced Cardiac Injury
- Reduced Cardiac Output
- Reduced Cardiovascular Disease
- Reduced Cardiovascular Disease Mortality
- Reduced Cardiovascular Dysfunction
- Reduced Cardiovascular Event
- Reduced Cardiovascular Mortality
- Reduced Cause-Specific Mortality
- Reduced Central Blood Pressure
- Reduced Cholesterol Metabolism
- Reduced Community Healthcare Costs
- Reduced Contrast-Induced Acute Kidney Injury
- Reduced Coronary Heart Disease Risk
- Reduced Cumulative Incidents of CIDs in Smokers
- Reduced Cumulative Morbidity Rates
- Reduced Dephosphorylated-Uncarboxylated Matrix Gla Protein Level
- Reduced Disease Incidence
- Reduced Disease Progression
- Reduced Dyslipidemia Parameters
- Reduced Exhaustion During Stress Test
- Reduced Flavonoid Levels
- Reduced HDL Cholesterol Level
- Reduced HDL Levels
- Reduced HMG-CoA Reductase Inhibition
- Reduced Harmful Lipid Levels
- Reduced Heart Failure
- Reduced Heart Rate Variability
- Reduced High-Density Lipoprotein (HDL) Cholesterol
- Reduced High-Density Lipoprotein Cholesterol Level
- Reduced High-Sensitivity C-Reactive Protein Level
- Reduced Homocysteine Level
- Reduced Hospitalisation
- Reduced Hydrogen Sulfide Level
- Reduced Hypercholesterolemia
- Reduced Hypercholesterolemia Incidence
- Reduced Hyperlipidemia Symptoms
- Reduced Hypertension
- Reduced ICAM-1 Level
- Reduced In-hospital Mortality
- Reduced Incidence of Cardiovascular Disease
- Reduced Inflammatory Biomarker Level
- Reduced Intimal Thickening
- Reduced Ischemic Heart Disease Mortality
- Reduced LDL Cholesterol
- Reduced LDL Levels
- Reduced LDL Oxidation
- Reduced Lipid Profiles
- Reduced Low-Density Lipoprotein Cholesterol
- Reduced Low-Density Lipoprotein Level
- Reduced Lymphocytic Genome Damage
- Reduced Lysophosphatidylcholine Level
- Reduced Monocyte Adhesion
- Reduced Morbidity
- Reduced Mortality
- Reduced Mortality Rate
- Reduced Mortality Risk
- Reduced Myeloperoxidase (MPO) Concentration
- Reduced Myeloperoxidase Levels
- Reduced Myocardial Infarct Size
- Reduced Myocardial Injury
- Reduced Myocardial Injury Cytokines
- Reduced Nitric Oxide Level
- Reduced Nitric Oxide Production
- Reduced Non-Communicable Disease Risk
- Reduced Non-HDL Cholesterol
- Reduced Non-High-Density Lipoprotein Cholesterol
- Reduced Non-Infectious Complication Morbidity
- Reduced Oxidized Low-Density Lipoprotein Level
- Reduced Plaque
- Reduced Plasma Homocysteine Levels
- Reduced Post-Exercise Serum Amyloid A Increase
- Reduced Postprandial Triacylglycerol Response
- Reduced Protein Oxidation
- Reduced Serum C-reactive Protein Levels
- Reduced Serum Cholesterol Levels
- Reduced Serum LDL Levels
- Reduced Serum Lipid Levels
- Reduced Serum Plasminogen Activator Inhibitor-1
- Reduced Serum Total Cholesterol Levels
- Reduced Soluble VCAM-1 Levels
- Reduced Symptoms of High-Fat Diet Pathologies
- Reduced TMAO Level
- Reduced TMAO Production
- Reduced Thrombosis
- Reduced Total Cholesterol
- Reduced Total Cholesterol Levels
- Reduced Total Cholesterol to HDL Cholesterol Ratio
- Reduced Total Lipid Levels
- Reduced Triglyceride Levels
- Reduced Triglyceridemia
- Reduced Trimethylamine N-oxide Levels
- Reduced VLDL Cholesterol Level
- Reduced Vascular Damage
- Reduced Vascular Restenosis
- Reduced Very Low-Density Lipoprotein
- Reduced Yolk Cholesterol Content
- Reduced hsCRP Level
- Regulated Blood Lipid Levels
- Regulated Lipid Metabolism
- Regulated Lipid Metabolism in Epididymal Fat Pads
- Restored HDL Levels
- Restored Lipid Metabolism
- Safety Comparable to Control
- Stabilized Plasma Cholesterol Levels
- Stabilized Visceral Fat Area
- Stable High-Density Lipoprotein Cholesterol Level
- Stable Plasma Cholesterol Levels
- Unchanged Plasma Lipid Levels